Actively Recruiting
Cryopreserved Human Umbilical Cord as a Meningeal Patch in Fetoscopic Spina Bifida Repair
Led by The University of Texas Health Science Center, Houston · Updated on 2025-08-13
100
Participants Needed
1
Research Sites
678 weeks
Total Duration
On this page
Sponsors
T
The University of Texas Health Science Center, Houston
Lead Sponsor
E
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective is to test the efficacy of a laparotomy-assisted fetoscopic surgical approach to cover spina bifida spinal cord developmental defects using cryopreserved human umbilical cords (NEOX Cord 1K®) as a meningeal and skin patch.
CONDITIONS
Official Title
Cryopreserved Human Umbilical Cord as a Meningeal Patch in Fetoscopic Spina Bifida Repair
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female with singleton pregnancy
- Gestational age between 19 and 25 5/7 weeks at screening and 22 to 25 6/7 weeks at surgery
- Maternal age 18 years or older
- Pre-pregnancy body mass index of 45 kg/m2 or less
- No risk factors for preterm birth such as short cervix less than 20 mm or previous preterm delivery
- No previous uterine incision in the active uterine segment
- Willingness to undergo open fetal repair if fetoscopic surgery is unsuccessful
- Fetus diagnosed with spina bifida defect between T1 and S1 vertebral levels
- Fetus has Chiari II malformation
- No evidence of fetal spinal kyphosis
- No major life-threatening fetal anomalies unrelated to spina bifida
- Normal fetal karyotype, normal chromosomal microarray analysis, or chromosomal microarray with variants of unknown significance (fluorescence in situ hybridization acceptable if 24 weeks or older)
You will not qualify if you...
- Non-resident of the United States
- Multifetal pregnancy
- Poorly controlled insulin-dependent pregestational diabetes or poorly controlled insulin-dependent A2 diabetes mellitus
- Current or planned cerclage or history of incompetent cervix
- Placenta previa or placental abruption
- Short cervix less than 20 mm
- Obesity with body mass index over 45 kg/m2
- Previous spontaneous singleton delivery before 37 weeks gestation
- Maternal-fetal Rh isoimmunization, Kell sensitization, or history of neonatal alloimmune thrombocytopenia
- HIV, Hepatitis B, or Hepatitis C positive status
- Uterine anomalies such as large or multiple fibroids or mullerian duct abnormalities that cannot be avoided during surgery
- Other medical conditions contraindicating surgery or general anesthesia
- Lack of a support person
- Inability to comply with travel and follow-up requirements
- Failure to meet psychosocial standardized assessment criteria
- Participation in other intervention studies affecting maternal or fetal outcomes
- Maternal hypertension
- Zika virus positivity
- Allergy or history of drug reaction to Amphotericin B
- Fetal major anomalies unrelated to spina bifida
- Fetal kyphosis of 30 degrees or more
- Ventriculomegaly greater than 15 mm with no movements at hip and knee joints
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
R
Ramesha Papanna, MD, MPH
CONTACT
S
Stephanie W Conaway, BSN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here